December 2013 A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.
November 2013 More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
September 2013 Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.
May 2013 A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.
March 2013 People who use prescription opiates nonmedically are more likely to consider suicide than those who use these medications only appropriately or not at all. A recent NIDA-supported study also disclosed that the risk for suicidal thoughts remains elevated after cessation of use.
February 2013 Fewer teens are using cigarettes, alcohol, and most illicit drugs, according to NIDA’s latest Monitoring the Future study. Troubling trends persist in marijuana use, however, and nonmedical prescription drug use remains a concern.
September 2012 New vaccines that aim to promote recovery from cocaine and heroin abuse showed promise in animal testing. Both vaccines induced rats’ immune system to produce high titers of antibodies that inhibit the target drug from reaching the brain. The rats’ behaviors when given access to the target drug indicated that the vaccines reduced the reinforcing effects that, in recovering people, can cause lapses to turn into relapses.
July 2012 Fewer than 12 percent of adolescents who meet diagnostic criteria for prescription opioid abuse or dependence receive any treatment, according to an analysis of data from the 2005 to 2008 National Survey on Drug Use and Health. The most common reason the adolescents gave for not receiving treatment was their lack of perceived need for it.
July 2012 Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.
Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.